Spiegel D M, Costante N, Janiga A M, Haas M, Soltani K
Department of Medicine, University of Chicago, Ill 60637.
Am J Nephrol. 1992;12(5):330-5. doi: 10.1159/000168468.
These studies were designed to track the cutaneous deposition of beta 2-microglobulin (beta 2M) in patients on chronic hemodialysis, patients with chronic renal insufficiency and patients with successful renal transplants. Immunoperoxidase staining of skin biopsies from dialysis patients demonstrated significantly increased amounts of beta 2M compared to controls (p < 0.01). There was a strong positive correlation between the skin beta 2M content and the years of dialysis treatment. Renal transplant recipients had decreased skin content of beta 2M compared to hemodialysis patients. There was no difference in the skin beta 2M content in patients with chronic renal insufficiency not on hemodialysis and controls. No dialysis patient had amyloid in the skin by Congo red stain. We conclude that beta 2M accumulates in the skin of patients on chronic hemodialysis. This beta 2M is not in the form of amyloid. Successful renal transplantation allows for the removal of beta 2M from the skin indicating that beta 2M not in the form of amyloid can be mobilized from tissue sites.
这些研究旨在追踪慢性血液透析患者、慢性肾功能不全患者以及肾移植成功患者皮肤中β2-微球蛋白（β2M）的沉积情况。与对照组相比，透析患者皮肤活检组织的免疫过氧化物酶染色显示β2M含量显著增加（p < 0.01）。皮肤β2M含量与透析治疗年限之间存在强正相关。与血液透析患者相比，肾移植受者皮肤中β2M含量降低。未进行血液透析的慢性肾功能不全患者与对照组的皮肤β2M含量无差异。通过刚果红染色，未发现透析患者皮肤中有淀粉样物质。我们得出结论，β2M在慢性血液透析患者的皮肤中蓄积。这种β2M不是淀粉样物质的形式。成功的肾移植可使皮肤中的β2M清除，这表明非淀粉样物质形式的β2M可从组织部位动员出来。
